- Global Pharma News & Resources

Company Profile for Inflection Biosciences Ltd

Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the IBL-300 series (PIM/PI3K/mTOR inhibitors) and IBL-202 (PIM/PI3K inhibitor) selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of treatment resistant solid tumours and haematological malignancies. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit

Company:   Inflection Biosciences Ltd

Headquarters Address:


Suite 15, Anglesea House, Carysfort Avenue,
Blackrock, Co. Dublin


Main Telephone: +35314003615

Type of Organization: Private
Industry: Biotechnology
Key Executives: CEO: Darren Cunningham
Director of R&D: Michael O'Neill
Contact: Darren Cunningham
Phone: +35314003615

View source version on

Editor Details

Last Updated: 01-Nov-2018